Fate Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell FATE and other ETFs, options, and stocks.About FATE
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates.
CEOBahram Valamehr
CEOBahram Valamehr
Employees181
Employees181
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded2007
Founded2007
Employees181
Employees181
FATE Key Statistics
Market cap128.04M
Market cap128.04M
Price-Earnings ratio-0.83
Price-Earnings ratio-0.83
Dividend yield—
Dividend yield—
Average volume1.05M
Average volume1.05M
High today$1.12
High today$1.12
Low today$1.05
Low today$1.05
Open price$1.07
Open price$1.07
Volume1.41M
Volume1.41M
52 Week high$2.93
52 Week high$2.93
52 Week low$0.6611
52 Week low$0.6611
Stock Snapshot
As of today, Fate Therapeutics(FATE) shares are valued at $1.06. The company's market cap stands at 128.04M, with a P/E ratio of -0.83.
As of 2025-12-05, Fate Therapeutics(FATE) stock has fluctuated between $1.05 and $1.12. The current price stands at $1.06, placing the stock +1.0% above today's low and -5.3% off the high.
Fate Therapeutics(FATE) shares are trading with a volume of 1.41M, against a daily average of 1.05M.
In the last year, Fate Therapeutics(FATE) shares hit a 52-week high of $2.93 and a 52-week low of $0.66.
In the last year, Fate Therapeutics(FATE) shares hit a 52-week high of $2.93 and a 52-week low of $0.66.
Analyst ratings
50%
of 12 ratingsBuy
50%
Hold
50%
Sell
0%
People also own
Based on the portfolios of people who own FATE. This list is generated using Robinhood data, and it’s not a recommendation.